Abstract Details

Title Trends in Outcome and Hospitalization Charges of Pediatric Patients Admitted with Myasthenia Gravis Treated with Plasmapheresis in the United States. Data from Kids' Inpatient Database (KID) 1997-2009

Topic Child Neurology/Developmental Neurobiology

Presentation(s) P03 - (-)

Poster/Presentation
Number 005

Objective

Background BACKGROUND: Over the past decade, plasmapheresis have been extensively used to treat MG crisis.

Design/Methods DESIGN/METHODS: We determined the rates of occurrence, in-hospital outcomes, and mean hospital charges for pediatric patients hospitalized with MG treated with plasmapheresis from 1997 to 2009 using Kids inpatient Database (KID).

Results RESULTS: From 1997 to 2009, 10% (2003) to 23% (2000) of MG patients were treated with plasmapheresis. There was a steady increase in the number of MG patients treated with plasmapheresis from 1997 (25) to 2009 (52). Ther was a significant variation of average patient age during the study time period with a minimum of 11.9±5.7 years in 1997 and a maximum of 13.2±5.3 years in 2009 (p=0.014). Female predominance was observed in all time periods. The average length of stay was not significantly different from 1997 to 2009. The minimum average length of stay was 4.7±5.4 days in 2003 and the maximum was 6.3±6.5 days in 1997 (p=0.2). The vast majority of patients were discharged to home in all studied time periods. During the studied time periods there was only one death, which occurred in 2006. There was a significant increase in average hospital charges over time: $37,426±43,609 in 1997 and $90,619±74,955 in 2009 (p<0.001). This difference persisted after adjustment for inflation.

Conclusions CONCLUSIONS: There was a significant increase in in-hospital charges of pediatric patients admitted for MG from 1997 to 2009, without any significant variation in average length of stay, death rate, and disposition status.

Authors/Disclosures
Zaid Al-Qudah, MD (Associate Specialist Inc.) PRESENTER	No disclosure on file
Kailash P. Bhatia, MD, FAAN (UCL)	Dr. Bhatia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Bhatia has received publishing royalties from a publication relating to health care.
Rania A. Elenein, MD (Jefferson Health NJ)	Dr. Elenein has nothing to disclose.
Wenzhuan He, MD (UPMC Susquehanna Neurology)	Dr. He has nothing to disclose.
Nizar Souayah, MD, FAAN (NJMS)	Dr. Souayah has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Souayah has received publishing royalties from a publication relating to health care.
John B. Bodensteiner, MD, FAAN	Dr. Bodensteiner has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for American Board of Psychiatry and Neurology.

��ɫ��

��ɫ��